Leave message
Can’t find what you’re looking for?
Fill out this form to inquire about our custom protein services!
Inquire about our Custom Services >>
Limited Edition Golden Llama is here! Check out how you can get one. 
Limited Edition Golden Llama is here! Check out how you can get one.
Offering SPR-BLI Services - Proteins provided for free!Get your ComboX free sample to test now!
Time Limited Offer: Welcome Gift for New Customers ! Shipping Price Reduction for EU Regions
| Cat. No. | Especies | Descripción del producto | Estructura | Pureza | Característica |
|---|---|---|---|---|---|
| ILP-HP2H3 | Human | PE-Labeled Human IL-1 RAcP / IL-1 R3 Protein, His Tag (Site-specific conjugation) |  |
||
| ILP-HF223 | Human | FITC-Labeled Human IL-1 RAcP / IL-1 R3 Protein, His Tag |  |
|
|
| ILP-H82F5 | Human | Biotinylated Human IL-1 RAcP / IL-1 R3 Protein, Fc,Avitag™ (MALS verified) |  |
|
|
| ILP-C52H5 | Cynomolgus | Cynomolgus IL-1 RAcP / IL-1 R3 Protein, His Tag |  |
|
|
| ILP-M52H5 | Mouse | Mouse IL-1 RAcP / IL-1 R3 Protein, His Tag |  |
|
|
| ILP-H82E5 | Human | Biotinylated Human IL-1 RAcP / IL-1 R3 Protein, His,Avitag™ (MALS verified) |  |
|
|
| ILP-H5256 | Human | Human IL-1 RAcP / IL-1 R3 Protein, Fc Tag |  |
|
|
| ILP-H5225 | Human | Human IL-1 RAcP / IL-1 R3 Protein, His Tag (MALS verified) |  |
|
Immobilized Human Anti-IL1RAP Human IgG1 at 1 μg/mL (100 μL/well) can bind Biotinylated Human IL-1 RAcP Protein, Fc,Avitag (Cat. No. ILP-H82F5) with a linear range of 0.5-16 ng/mL (QC tested).
The purity of Biotinylated Human IL-1 RAcP Protein, Fc,Avitag (Cat. No. ILP-H82F5) is more than 85% and the molecular weight of this protein is around 155-175 kDa verified by SEC-MALS.
| Name | Research Code | Research Phase | Company | Indications | Clinical Trials |
|---|---|---|---|---|---|
| Nidanilimab | CAN-04 | Phase 2 Clinical | Lund University Foundation | Solid tumours; Biliary Tract Neoplasms; Squamous Cell Carcinoma of Head and Neck; Triple Negative Breast Neoplasms; Pancreatic Neoplasms; Carcinoma, Transitional Cell; Colorectal Neoplasms; Carcinoma, Pancreatic Ductal; Carcinoma, Non-Small-Cell Lung; Melanoma | Details |
| CCTx-001 | CCTx-001 | Phase 2 Clinical | Advesya SAS | Leukemia, Myeloid, Acute | Details |
| SAR-445399 | SAR-445399 | Phase 1 Clinical | Sanofi | Inflammation | Details |
| GSK3903371 | GSK3903371 | Clinical | Glaxosmithkline Plc | Neoplasms | Details |
| Nidanilimab | CAN-04 | Phase 2 Clinical | Lund University Foundation | Solid tumours; Biliary Tract Neoplasms; Squamous Cell Carcinoma of Head and Neck; Triple Negative Breast Neoplasms; Pancreatic Neoplasms; Carcinoma, Transitional Cell; Colorectal Neoplasms; Carcinoma, Pancreatic Ductal; Carcinoma, Non-Small-Cell Lung; Melanoma | Details |
| CCTx-001 | CCTx-001 | Phase 2 Clinical | Advesya SAS | Leukemia, Myeloid, Acute | Details |
| SAR-445399 | SAR-445399 | Phase 1 Clinical | Sanofi | Inflammation | Details |
| GSK3903371 | GSK3903371 | Clinical | Glaxosmithkline Plc | Neoplasms | Details |
This web search service is supported by Google Inc.
A-Z
